Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar;16(1):29-34.
doi: 10.4274/tjod.galenos.2019.56255. Epub 2019 Mar 27.

Cost-effectiveness of GnRH antagonist implementation on hCG injection day

Ayşe Zehra Özdemir  1 , Bülent Ayas  1 , Davut Güven  1 , Aysın Pınar Türkmen  1 , Çağrı Gülümser  2
Affiliations

Cost-effectiveness of GnRH antagonist implementation on hCG injection day

Ayşe Zehra Özdemir et al. Turk J Obstet Gynecol. 2019 Mar.

Abstract

Objective: To compare the outcomes of antagonist stimulation protocols and to compare the cost effectiveness.

Materials and methods: Between 2011 and December 2017, a total of 354 women who underwent intracytoplasmic sperm injection and controlled ovarian stimulation with antagonist protocols were enrolled in the study. The antagonist implementation on the day of human chorionic gonadotropin (hCG) was continued for 194 of women, whereas the antagonist was stopped 36 hours before in 160 women. The stimulation outcomes of patients and cost-effectiveness of the regimens were compared.

Results: There was a significant difference between the groups in terms of number of cryopreserved embryos, mature/immature oocyte ratio, and embryo transfer cancellations (p<0.05). The median value for the mature/immature oocyte ratio was 1.1 (0.2-7.5) and 1 (0.5-15) (p=0.001), and the ET cancellation was 5.3% vs. 1% for group 1 and 2, respectively (p=0.037). There was no difference between the groups in terms of pregnancy rates (p=0.197).

Conclusion: No difference was found in the clinical pregnancy rates between the two groups. For this reason, the cessation of antagonist implementation on the day of hCG seems more advantageous in terms of cost-effectiveness and fewer injections.

Keywords: cost effectiveness; pregnancy rates; Controlled ovarian stimulation.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: No conflict of interest was declared by the authors.

References

    1. Kolibianakis EM, Tarlatzis B, Devroey P. GnRH antagonists in IVF. Reprod Biomed Online [Internet] 2005;10:705–12. - PubMed
    1. Copperman AB, Benadiva C. Optimal usage of the GnRH antagonists: A review of the literature. Reprod Biol Endocrinol. 2013;11:1–13. - PMC - PubMed
    1. Gordon K, Hodgen GD. GnRH agonists and antagonists in assisted reproduction. Baillieres Clin Obstet Gynaecol. 1992;6:247–65. - PubMed
    1. Olivennes F, Belaisch-Allart J, Emperaire JC, et al. Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LHRH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin) Fertil Steril. 2000;73:314–20. - PubMed
    1. Johnston-MacAnanny EB, DiLuigi AJ, Engmann LL, Maier DB, Benadiva CA, Nulsen JC. Selection of first in vitro fertilization cycle stimulation protocol for good prognosis patients: gonadotropin releasing hormone antagonist versus agonist protocols. J Reprod Med [Internet] 2011;56:12–6. - PubMed

LinkOut - more resources